Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries

Reuters

2025/11/07

Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries

Overview

SIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year
Company attributes revenue decline to lower product sales, especially TPOXX deliveries
SIGA focuses on securing new procurement contracts for future revenue growth

Outlook

SIGA focuses on securing new procurement contracts for future revenue growth

Result Drivers

LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries
U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries
INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$6.40 mln

Analyst Coverage

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release: ID:nGNX7g5NW3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581486500"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581486500\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581486500?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581486500","market":"fut","top_or_hot":-1,"title":"Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries</title></head><body><p><span>Overview</span></p><ul><li><p>SIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year</p></li><li><p>Company attributes revenue decline to lower product sales, especially TPOXX deliveries</p></li><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Outlook</span></p><ul><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries</p></li><li><p>U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries</p></li><li><p>INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$6.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX7g5NW3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAntiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 05:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries</title></head><body><p><span>Overview</span></p><ul><li><p>SIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year</p></li><li><p>Company attributes revenue decline to lower product sales, especially TPOXX deliveries</p></li><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Outlook</span></p><ul><li><p>SIGA focuses on securing new procurement contracts for future revenue growth</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries</p></li><li><p>U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries</p></li><li><p>INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$6.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX7g5NW3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SIGA","symbol_name":"SIGA Technologies Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1I2:1","article_id":"2581486500","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581486500","pubTimestamp":1762463630,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveriesOverviewSIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last yearCompan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SIGA":"SIGA Technologies Inc","BK4007":"制药","BK4583":"猴痘概念"},"translate_title":"抗病毒疗法开发商SIGA第三季度收入因TPOXX交付量下降而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SIGA":0.9},"content_text":"Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveriesOverviewSIGA Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last yearCompany attributes revenue decline to lower product sales, especially TPOXX deliveriesSIGA focuses on securing new procurement contracts for future revenue growthOutlookSIGA focuses on securing new procurement contracts for future revenue growthResult DriversLOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveriesU.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveriesINTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six yearsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$6.40 mlnAnalyst CoverageThe stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months agoPress Release: ID:nGNX7g5NW3For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}